key: cord-0025659-urs21jv6
authors: Sapkota, Binaya; Saud, Bhuvan; Shrestha, Ranish; Al-Fahad, Dhurgham; Sah, Ranjit; Shrestha, Sunil; Rodriguez-Morales, Alfonso J
title: Heterologous prime–boost strategies for COVID-19 vaccines
date: 2021-12-16
journal: J Travel Med
DOI: 10.1093/jtm/taab191
sha: ca7102ff352281eb43aa5942d8265c331c5160b3
doc_id: 25659
cord_uid: urs21jv6

BACKGROUND/OBJECTIVE: Heterologous prime–boost doses of COVID-19 vaccines (‘mix-and-match’ approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in ‘Com-Cov2 trial’ in UK, and that of Oxford and Pfizer vaccines in ‘CombivacS trial’ in Spain. Later, other heterologous combinations of CoronaVac (DB15806), Janssen (JNJ-78436735), CanSino (AD5-nCOV) and other were also being trialled to explore their effectiveness. Previously, such a strategy was deployed for HIV, Ebola virus, malaria, tuberculosis, influenza and hepatitis B to develop the artificial acquired active immunity. The present review explores the science behind such an approach for candidate COVID-19 vaccines developed using 11 different platforms approved by the World Health Organization. METHODS: The candidate vaccines’ pharmaceutical parameters (e.g. platforms, number needed to vaccinate and intervals, adjuvanted status, excipients and preservatives added, efficacy and effectiveness, vaccine adverse events, and boosters), and clinical aspects must be analysed for the mix-and-match approach. Results prime–boost trials showed safety, effectiveness, higher systemic reactogenicity, well tolerability with improved immunogenicity, and flexibility profiles for future vaccinations, especially during acute and global shortages, compared to the homologous counterparts. CONCLUSION: Still, large controlled trials are warranted to address challenging variants of concerns including Omicron and other, and to generalize the effectiveness of the approach in regular as well as emergency use during vaccine scarcity.

Till 7 December 2021, 136 coronavirus disease 2019 vaccines are in various phases of clinical trials (10 in phase 4 and 29 in phase 3), while 194 are in the pre-clinical phase. 1 Generally, vaccines require multiple shots, and receivers should be injected with the same type of biological preparation in the second dose as the first (known as 'homologous primeboost' vaccination). 2 The first dose primes the body's immune system and the second dose amplifies the immune response at an effective level with a different vaccine product than the first dose. Priming would be for the primary series where two doses use 'mix-and-match' strategies, and boosting would be suitable for those vaccines with the completed primary schedule but are usually done with another vaccine platform. The strategy of combining different vaccines during the prime and boost phases that target the same antigen (known as the 'heterologous primeboost' or 'mix-and-match' strategy) has already been successfully deployed for the treatment of numerous conditions, including human immunodeficiency viruses (HIV), 3 ,4 Ebola virus disease (EVD), 5 malaria, tuberculosis, influenza and hepatitis B. 4 The World Health Organization (WHO), with support from the Strategic Advisory Group of Experts (SAGE) on Immunisation and its COVID-19 Vaccines Working Group has been evaluating evidence on the use of heterologous priming schedules. Heterologous boosting refers to administering a vaccine from a vaccine platform different from the vaccine used to complete the primary vaccine series. 6 Nevertheless, the value of this strategy awaits results yet to be developed from a clinical trial for the treatment of COVID- 19. In EVD vaccines, the prime shot of adenovirus vector carrying the gene for the viral protein, followed by a booster of modified vaccinia Ankara encoding the same viral gene, was adopted. 7 ,8 The same approach was adopted for the COVID-19 vaccine being developed by the City of Hope Medical Center, USA (COH04S1). 1 Two unique vaccine administrations targeting the same or overlapping antigens but using different delivery systems or vectors are used, intended to improve immunogenicity and efficacy compared to the same vaccine in two shots. 9 The combination of DNA vaccine, encoding the spike protein (S) and S1 recombinant protein vaccine, was shown to induce high neutralizing antibody response and T-cell response in animal models. 10 Studies showed that the heterologous vaccine administration could overcome the adverse effects of immune response to viral vectors 11 and improve immunogenicity. 12 However, Iacobucci (2021) reported that the mix-and-match approach for Oxford and Pfizer vaccines (AZD1222 and BNT162b2, respectively) caused mild-to-moderate reactions. 13 Shaw et al. (2021) , in their interim safety analysis, reported that haematology and biochemistry profiles were similar in both heterologous and homologous uses of these vaccines. Vaccineassociated events (VAEs) were of grade 2 severity or less in the heterologous scheme and without thrombocytopenia for Day 7 post-boost. However, they observed increased systemic reactogenicity with the boost dose of heterologous schedules, compared to the homologous, which was manageable with paracetamol. 14 Generally, immunocompetent individuals develop an immune response to any infectious agents as the innate immune responses such as cytokine and interferon secreted by the immune cells act immediately to show antiviral activity once the antigen enters the body. 15 ,16 Also, the specific immune response acts against the virus or antigen after 6-8 days of infection due to T cell (cellular response) and B cell (antibody response). 15 The cellular immune response components, i.e. CD8+ cytotoxic T cells, kill the virus-infected cells with the help of perforin and granzymes and slow down and stop the infection, whereas CD4+ helper T cells cause B cells activation for antigen-specific antibody production. The activated B cells then produce plasma cells (i.e. antibodies-producing cells) and memory B cells respond to the antigen instantly if the same antigen is encountered in future. 15 In COVID-19, the body produces antibodies against the viral S (S1 and S2 subunit) and N protein. The neutralizing antibodies target the receptor-binding domain (RBD) present in the S1 subunit, 17 whereby IgM, IgG and IgA neutralizing antibodies appeared. All the antibodies against the viral protein can be detected in serum within 1-3 weeks after infection. 15 Specifically, seroconversion of IgM and IgG occurs at ∼2 weeks post-onset of symptoms and reaches neutralizing titre in 14-20days. 18 A study conducted in Italy revealed that serum anti-spike IgG antibody titre increased from 16 400 to 23 800 arbitrary units per millilitre. 19 Neutralizing antibody titre may remain stable for 75-180 days in the case of COVID-19. 20 A large cohort study also found anti-S IgG antibody titre stable over 5 months for the virus neutralization. 21 IgM reaches a lower level by the fifth week and almost disappears by the seventh week, whereas IgG antibodies persist for a long time. 22,23 Serum IgA antibody's function in SARS-CoV-2 infection is not yet known, but secretory IgA antibody provides local mucosal immunity. 24 Studies noted that memory B cells specific for SARS-CoV-2 spike (S) protein were found in the individuals recovered from the infection. 25, 26 The level of S-specific memory B cells remained stable for more than 5 months after the infection and get associated with viral neutralization, unlike antibodies. 27 In normal conditions, resting (RM) subset of memory B cells is prevalent but decreases during many viral infections. A recent study also found that severe COVID-19 infection-activated (AM) and tissue-like (TLM) subsets were significantly increased. 28 Providing the identical vaccine in the first and subsequent shots may not always be possible, especially during pandemics such as COVID-19, due to manufacturing delays and poor supply systems. The Public Health England policy, therefore, permits the use of different vaccines under certain conditions. 2 Heterologous prime-boost strategy is being studied to evaluate its effectiveness against COVID-19 in the UK (called 'Com-Cov2 trial' to test for Oxford, Pfizer, Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines) in 1050 volunteers 5, 29 and Spain ('CombivacS trial' to test for Oxford and Pfizer vaccines) in 663 volunteers. 30 Preliminary data of these trials revealed that participants in the heterologous groups experienced minor VAEs such as fever (more in the UK trial and less in the Spanish trial). 30 Nevertheless, other combinations of vaccines have to be trialled to identify the best combination for the treatment of COVID-19. Hence, the present review explores the strategy of heterologous prime-boost regimes as a robust means of vaccinating large numbers of people safely and efficiently in the face of challenging vaccine rollout conditions.

The primary factor in heterologous priming is the lack of availability or limited and unpredictable supply of the same COVID-19 vaccine in several settings. Such interchangeability of vaccine products would allow for their flexible application. Other key reasons include investigating the use of heterologous priming concerning reactogenicity, immunogenicity and vaccine efficacy (VE). However, heterologous priming should be instituted only when evidence supporting the said parameters is available. 6

The available data on heterologous priming vaccine schedules have been continuously monitored, with guidance being available in some product-specific interim recommendations (such as for mRNA vaccines, i.e. BNT162b2 or mRNA-1273, and ChAdOx1-S [recombinant] vaccines to date). The WHO recommends that the same vaccine product be used for both doses of COVID-19 vaccination even during emergency use with a twodose primary series schedule. However, no additional doses of either vaccine are recommended if different COVID-19 vaccine products are administered in the two doses. The mix-and-match schedules currently available constitute off-label use of respective vaccines and, as such, should only be used when the benefits outweigh the risks. 6 Studies on the immune response after the first dose of ChAdOx1-S [recombinant] followed by an mRNA vaccine (i.e. BNT162b2 or mRNA-1273) show higher neutralizing antibody levels and higher T cell-mediated immune response compared to two doses of either of the two. The sequence of ChAdOx1-S [recombinant] for the first dose followed by the mRNA vaccine for the second dose was more immunogenic than the reverse. However, these findings should be carefully interpreted due to limited sample sizes and lack of follow-ups, about safety profiles, immunological outputs and clinical impacts. The initial results on short-term VE following a heterologous schedule were obtained from Denmark, showing an 88% (95% CI: 83-92%) effectiveness when following the said sequence. The VE result was similar to VE of two mRNA vaccine doses in a population-wide register-based study when the SARS-COV-2Alpha variant was dominant. More observational data on safety and effectiveness are expected. 6 The candidate vaccines' pharmaceutical parameters (e.g. platforms, number needed to vaccinate and intervals, adjuvanted status, excipients and preservatives added, efficacy and effectiveness, VAEs, boosters), and clinical aspects must be analysed for the mix-and-match approach. 1 Out of many different subunit vaccines, only the PS platform has been trialled for COVID-19 vaccines due to safety issues. However, as adjuvants are usually required with such vaccines, there is a potential risk of VAEs from adjuvants. 31 Two types of whole virus COVID-19 vaccines (i.e. live attenuated and inactivated) have been trialled for COVID-19, necessitating stringent safety checks to ensure that the attenuated viruses do not revert to wild-type. 31 Killed vaccines may not produce life-long immunity and require booster doses at different time intervals, 32 and VLPs (assembled from viral structural proteins) have adjuvant properties. 33 The endogenous antigen production would stimulate both humoral and cellular immune responses by a single dose. 31 Currently, administered mRNA vaccines developed by Pfizer and Moderna were found to produce required immunogenicity against SARS-CoV-2. 34 Previously, DNA vaccines were approved only for veterinary 35 and will be a novel approach for human use in the case of COVID. 36

Inactivated vaccines were traditionally developed without adjuvant, but it has been used in some COVID-19 vaccines to promote immunogenicity. 10 Novavax is a recombinant glycoprotein vaccine adjuvanted with Matrix M; Sanofi Pasteur (VAT00002), Vaxine (NCT04453852) and Medigen Vaccine Biologics (MVC-COV1901) also used S protein with adjuvant; Clover Biopharmaceuticals (SCB-2019) and Nanogen Pharmaceutical Biotechnology (NANOCOVAX) used S protein with alum adjuvant, while Vaxart vaccine (VXA-CoV2-1) is an Ad5 adjuvanted oral vaccine. 1 However, the exact immunologic basis of adjuvants like aluminium salts (e.g. aluminium hydroxide, aluminium phosphate) is still unknown. Although adjuvanted aluminium salts are generally safe, 37 these may cause local reactions (e.g. injection site pain, inflammation, granulomas formation, abscesses, lymphadenopathy and skin ulceration) and systemic reactions (e.g. fever, headache, malaise, diarrhoea, arthralgia and myalgia). 38

Pfizer and Moderna vaccines contain polyethylene glycol (PEG or macrogol) as the major excipients (i.e. compounds other than the active pharmaceutical ingredient (API) that are intentionally included in a drug delivery system that has been assessed for safety) that stabilize the lipid nanoparticles containing mRNA. In contrast, Oxford and Johnson & Johnson (JNJ-78436735) vaccines contain polysorbate 80 (Tween 80). These excipients are most frequently associated with allergic reactions. 39 The WHO draft does not indicate the presence of any preservative (e.g. thiomersal or other), antimicrobials (e.g. neomycin, polymyxin B or streptomycin) and medium of egg cultures in any candidate vaccine. 1 Therefore, preservative and egg culture-related VAEs (e.g. anaphylactic reactions) seem not to be in the formulation of any of the COVID-19 vaccines.

It is still under investigation how many people need vaccination against COVID-19 before population immunity is achieved and how effective the vaccines are against the new variants of COVID-19. 40 Previously, it was reported that ∼67% of the population need to be vaccinated for herd immunity against SARS-CoV-2. 30 The prime concerns about the factors that need to be in place for this target to be achieved are the requirements of scale-up of manufacturing capacities and maintenance of proper distribution channels and supply systems worldwide. 31, 41 Based on the mathematical models, it has been projected that low-and middle-income countries would suffer from the disproportionate distributions of vaccines till 2023 due to hurdles such as cold-chain requirements, manufacturing delays and imbalanced supply channels. 42 Of all candidate vaccines under various phases of clinical trials till 7 December 2021, 114 (84%) were injectable (104 (76%) intramuscular, 5 (4%) subcutaneous, and 5 (4%) intradermal), 8 (6%) intranasal, 4 (3%) oral, 1 (1%) aerosol and 1 (1%) inhaled. Eighty-three (61%) candidate vaccines required two shots (43 on Day 0-28, 33 on Day 0-21 and 7 on Day 0-14), 21 (15%) required a single shot and two (1%) required 3 jabs (on Day 0-28-56). 1

Immunogenicity of vaccines is usually worse among older adults due to immunosenescence caused by the decreased availability of T-cells and B-cells. Therefore, immune response assessment is necessary for COVID-19 vaccine development for these groups, adjuvanted vaccines being suitable for them. 43 The Oxford vaccine was found to have low reactogenicity and mild side effects, safe and well-tolerated among older adults. 14 ,43,44 However, few adverse events were reported with the boost dose with declining reactogenicity on advancing age, necessitating low dose for all age groups. 43 Both the Pfizer and Moderna vaccines have also been shown to produce mild-to-moderate reactions, with very few severe allergic reactions. 34 Mix-and-match approach for Oxford and Pfizer vaccines caused more mild-to-moderate reactions than the standard regimen. Fever was recorded among 37 (34%) of 110 recipients of Oxford vaccine as prime and Pfizer as boost dose, compared with 11 (10%) of 112 recipients of Oxford for both prime and boost. Fever was reported in 47 (41%) of 114 recipients following the deployment of the Pfizer vaccine as prime and Oxford as boost dose, compared with 24 (21%) of 112 recipients of Pfizer as both prime and boost. Although similar increases were also seen for other reactions such as chills, headaches and myalgia, such reactions were transient. 13

Boosters for COVID-19 vaccines may be required because the first dose can only unreliably activate the body's immune system, and the second provides consistent protection against COVID-19. Immunity is better three months after the Moderna vaccine and six months after Oxford shots, but still, there is no evidence of how long immunity to COVID-19 persists after vaccination. Furthermore, since coronavirus is rapidly mutating (similar to the flu virus mutating every year), our immune cells may not recognize the mutated virus, and thus, we may need to administer a booster vaccine to tackle new strains. 

An ideal SARS-CoV-2 vaccine would elicit a protective response within one month of administration, and would develop the cell mediated, antibody mediated immune and mucosal immune responses in effective level with minimum adverse effects. Such response should remain for a minimum of 6 months after one or two vaccinations and should protect older adults and the immunocompromized. 11, 44 Additionally, it should be manufactured on a large scale. 31 Previously, adenoviral vectors were combined with DNA and poxviral vectors to enhance cellular and humoral immunity. However, homologous adenoviral regimens were not preferred due to the reduced potency of the second dose due to anti-vector immunity. 44

Both Com-Cov2 and CombivacS trials have tested heterologous combinations of only 4 and 2 COVID vaccines, respectively, developed with three platforms-VVnr, mRNA and PS. However, trials of vaccines developed in seven other platforms are still pending (Table 1) . Also, from the preliminary data generated, it is unclear whether mild-to-moderate VAEs are due to prime dose or heterologous boost. Until and unless all combinations are trialled in a diverse population, it would be premature to declare them safe and efficacious, and such trials will demand longitudinal studies. Therefore, we have to rely on the data generated from the ongoing currently. The heterologous prime-boost schemes for COVID-19 vaccinations have been included in the national vaccine policy of some countries while others are considering it. Brief review of heterologous prime-boost shots is presented in Table 2 .

Heterologous prime-boost approaches, after considering the candidate vaccines' platforms, number needed to vaccinate and intervals, adjuvanted status, excipients and preservatives added, efficacy and effectiveness, vaccine adverse events, and boosters, have shown safe and effective outputs among humans, proving the same as a milestone in vaccination campaigns, the primary benefit being the uninterrupted rollout and supply chain despite problems in one or two vaccine shots. Although large-scale controlled trials with all available permutations of COVID-19 vaccines are warranted to make the findings generalizable and applicable in the broader perspective, the beneficial results with heterologous approach in terms of improved immunogenicity, reactogenicity, safety, effectiveness and flexibility made it an alternative to the practitioners and policymakers globally.

Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization

COVID-19: vaccine brands can be mixed in "extremely rare occasions," says Public Health England

Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Could mixing COVID vaccines bolster immune response?

WHO. Interim statement on heterologous priming for COVID-19 vaccines

Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study

Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal

Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Heterologous prime-boost vaccination

COVID-19: fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

What we know about the COVID-19 immune response: the latest on COVID-19 immunity & the current global situation (Coronavirus Update 34

Innate immune sensing of coronavirus and viral evasion strategies

Antibodies and vaccines target RBD of SARS-CoV-2

Antibody responses in COVID-19: a review

SARS-CoV-2 antibody response in persons with past natural infection

Antibody-dependent enhancement and COVID-19: moving toward acquittal

Molecular basis of COVID-19 relationships in different species: a one health perspective

Interpreting diagnostic tests for SARS-CoV-2

Profile of specific antibodies to SARS-CoV-2: the first report

CDC. Interim guidelines for COVID-19 antibody testing

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time

Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help

A single-blind, randomised, phase II UK multi-Centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules -stage 2

Mix-and-match COVID vaccines trigger potent immune response

Next-generation vaccine platforms for COVID-19

Immunization guidelines. Dubai Health Authority Department of Public Health & safety

Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines

DNA vaccines against COVID-19: perspectives and challenges

The different types of COVID-19 vaccines

Commonly used adjuvant human vaccines: advantages and side effects

Comparative safety of vaccine adjuvants: a summary of current evidence and future needs

Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations

~:text=COVID%2D19%20vaccines%20are%20sa fe

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Optimism and caution for an inactivated COVID-19 vaccine

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Comparing the COVID-19 vaccines: how are they different

Heterologous ChA-dOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers

reactogenicity, and immunogenicity of homologous and heterologous primeboost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Eng

Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines

mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic

Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination

Neutralization of VOCs including Delta one year post COVID-19 or vaccine

The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Heterologous SARS-CoV-2 booster vaccinations -preliminary report

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

Heterologous prime-boost immunization with CoronaVac and Convidecia

SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorVvaccinated individuals compared with homologous BNT162b2 vaccination: results of a pilot prospective cohort study from Lebanon

Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming

The authors are thankful to Prof. Ketan Patel from the Biomedical School, University of Reading, UK for his contribution to the manuscript till its first revision. 

The authors declare that they have no competing interests.

The author(s) received no funding for this work.